Literature DB >> 21797660

Fentanyl for breakthrough pain: a systematic review.

Mellar P Davis1.   

Abstract

The purpose of this article is to systematically review the use of fentanyl as an analgesic for breakthrough pain. This article found that the oral transmucosal fentanyl (OTFC) had a quicker onset to analgesia than oral immediate-release opioids. Intranasal fentanyl (INFS) had a quicker onset to analgesia than buccal tablets, which in turn had a quicker onset to analgesia than OTFC. Patient acceptance and global rating of efficacy were greater for INFS than for buccal fentanyl. OTFC and INFS have been used effectively to reduce acute pain in children who are opioid-naive. Abuse and addiction to OTFC, fentanyl buccal tablets and INFS was low, owing to patient selection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21797660     DOI: 10.1586/ern.11.63

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  20 in total

Review 1.  Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications.

Authors:  Ruben S Vardanyan; Victor J Hruby
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

2.  Nasal delivery of fentanyl.

Authors:  Peter Watts; Alan Smith; Michael Perelman
Journal:  Drug Deliv Transl Res       Date:  2013-02       Impact factor: 4.617

3.  Fentanyl inhibits proliferation and invasion of colorectal cancer via β-catenin.

Authors:  Xiu-Lai Zhang; Min-Li Chen; Sheng-Li Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

4.  Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain.

Authors:  Harold Minkowitz; Janet Bull; R Charles Brownlow; Neha Parikh; Richard Rauck
Journal:  Support Care Cancer       Date:  2016-01-16       Impact factor: 3.603

5.  Acceptability and preferences of six different routes of drug application for acute breathlessness: a comparison study between the United Kingdom and Germany.

Authors:  Steffen T Simon; Anna Maria Niemand; Hamid Benalia; Raymond Voltz; Irene J Higginson; Claudia Bausewein
Journal:  J Palliat Med       Date:  2012-10-24       Impact factor: 2.947

Review 6.  Fentanyl for the treatment of tumor-related breakthrough pain.

Authors:  Helmar Bornemann-Cimenti; Mischa Wejbora; Istvan S Szilagyi; Andreas Sandner-Kiesling
Journal:  Dtsch Arztebl Int       Date:  2013-04-19       Impact factor: 5.594

Review 7.  A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients.

Authors:  Evelien J M Kuip; Maarten L Zandvliet; Stijn L W Koolen; Ron H J Mathijssen; Carin C D van der Rijt
Journal:  Br J Clin Pharmacol       Date:  2016-10-29       Impact factor: 4.335

Review 8.  Optimal management of breakthrough cancer pain (BCP).

Authors:  Y Escobar; A Mañas; J Juliá; R Gálvez; F Zaragozá; C Margarit; R López; A Casas; A Antón; J J Cruz
Journal:  Clin Transl Oncol       Date:  2012-12-21       Impact factor: 3.405

9.  A survey of Canadian cancer patients' perspectives on the characteristics and treatment of breakthrough pain.

Authors:  Gillian Bedard; Philippa Hawley; Liying Zhang; Marissa Slaven; Pierre Gagnon; Stuart Bisland; Margaret Bennett; Francois Tardif; Edward Chow
Journal:  Support Care Cancer       Date:  2013-05-02       Impact factor: 3.603

10.  Breakthrough cancer pain: a comparison of surveys with European and Canadian patients.

Authors:  Gillian Bedard; Andrew Davies; Rachel McDonald; Philippa Hawley; Alison Buchanan; Marko Popovic; Erin Wong; Edward Chow
Journal:  Support Care Cancer       Date:  2014-09-06       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.